

Access DB# 15419
For Jan Deland
Please

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Shahram Sharah Examiner #: 76656 Date: 6/20/2000
Art Unit: 1619 Phone Number 306-5400 Serial Number: 09/349,213
Mail Box and Bldg/Room Location CM12A12 Results Format Preferred (circle) PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Formulations having an antiviral AXN
Inventors (Please provide full names) H. BUCHHOLTZ, A. WAGNER, C. KRAUS,
J. MEDSKI
Earliest Priority Filing Date: 7/99

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

- (in all forms, tablet, lotion, capsule etc.)*
- Composition comprising preferably for treatment of Herpesviridae*
- (a) ISOQUERCITRIN as an active agent*
- (b) (and a carrier? anything)*
- (c) and a compound selected from the group recited in claim 11 see attached*
- (d) and a UV. filtering agent such as benzophenones, benzoylmethane, benzoylmethane, cinnamic acid esters, isoamyl methoxycinnamate, PABA, octylmethoxycinnamate, ZNO or TiO2, Salicylates, octocrylene,*

(EUSLEX 232, EUSLEX 9020) (Please also see attached)

STAFF USE ONLY		Type of Search	Vendors and cost where applicable
Searcher: <u>66</u>	NA Sequence (#) <u> </u>	STN <input checked="" type="checkbox"/>	
Searcher Phone #: <u>14498</u>	AA Sequence (#) <u> </u>	Dialog <u> </u>	
Searcher Location: <u> </u>	Structure (#) <u> </u>	Questel/Orbit <u> </u>	
Date Searcher Picked Up: <u>713</u>	Bibliographic <input checked="" type="checkbox"/>	Dr.Link <u> </u>	
Date Completed: <u>713</u>	Litigation <u> </u>	Lexis/Nexis <u> </u>	
Searcher Prep & Review Time: <u> </u>	Fulltext <u> </u>	Sequence Systems <u> </u>	
Clerical Prep Time: <u>60</u>	Patent Family <u> </u>	WWW/Internet <u> </u>	
Online Time: <u>80</u>	Other <u> </u>	Other (specify) <u> </u>	

LL

ACCESSION NUMBER: 2002:239045 USPATFULL
TITLE: Neuroprotective effects of mitogen-activated protein
kinase (MAPK) cascade inhibitors
INVENTOR(S): Baskys, Andrius, 10 Cool Brook, Irvine, CA, United
States 92612

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6451837	B1	20020917
APPLICATION INFO.:	US 2000-653065		20000901 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-151955P	19990901 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Gitomer, Ralph	
ASSISTANT EXAMINER:	Khare, Devesh	
LEGAL REPRESENTATIVE:	Cummings & Lockwood LLC	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	797	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is provided for therapeutic use of a class of compounds that are effective in protecting nerve cells from deterioration and cell death arising from degenerative disease, trauma or aging and may be used

to achieve a similar effect in male and female subjects with minimal adverse side effects. The method comprises administering a therapeutically effective dose of a natural or synthetic bioflavonoid that acts as an MAPK cascade antagonist. Examples of bioflavonoids that may be used in the present method are apigenin and 2-(2'-amino-3'-methoxyphenyl)-oxanaphthalen-4-one (PD098059).

SUMM . . . in vitro. MAPK cascade antagonists useful in treating cells of the nervous system include, for example, PD098059 and apigenin, or **pharmaceutically** acceptable salts of these compounds.

SUMM . . . in vitro. MAPK cascade antagonists useful in treating cells of the nervous system include, for example, PD098059 and apigenin, or **pharmaceutically** acceptable salts of these compounds.

DETD . . . orally, intramuscularly, transdermally, buccally, intravenously

or subcutaneously. Also, the bioflavonoid may be administered by dose or

by controlled release vehicles. **Pharmaceutically** acceptable salts of the compounds may also be used.

DETD As will be apparent to one skilled in the art from the disclosure herein, other bioflavonoids, or **pharmaceutically** acceptable salts of the bioflavonoids, may be used in the present method to achieve

neuroprotection. Specific examples of compounds that . . . invention are apigenin, apigenin, pelargonidin, versulin, cosmosetin, apioside, cosmosin, cosmosin cosmoside, baicalin, cirsimaritin, 6-hydroxyluteolin, luteolin, plantagin, rhoifolin, sorbavin, afrelin, hyperin, **isoquercitrin**, isorhamnetin, kaempferitrin, **kaempferol**-7-glucoside, oxyanin-A, **quercetin**, **quercitrin**, rhamnetin and rutin. Furthermore, any of these compounds may be supplied in the form of a prodrug that may be . . .

DETD The neuroprotective compounds used in the present invention can be

administered in **pharmaceutical** compositions. The recommended route of administration of the neuroprotective compound includes oral, intramuscular, transdermal, buccal, intravenous and subcutaneous. Methods of. . .

DETD The **pharmaceutical** compositions may be in the form of tablets, dragees, capsules, pills, solutions, suspensions, emulsions or ophthalmic preparations or any other appropriate form for delivery of **pharmaceutical** compositions. The **pharmaceutical** compositions in solid form may contain non-aqueous diluents, including for example fillers and extenders, binding agents, moisturizing agents, disintegrating agents, surface active agents, adsorptive carriers, lubricants or any other appropriate diluent known to one skilled in the art. **Pharmaceutical** compositions in liquid form may contain liquid diluents such as, for example, water, ethyl alcohol, propylene glycol or any other. . . .

DETD . . . A and Hori Y. Immunocytochemical distribution of gamma isoform of protein kinase C (PKC-gamma) following incomplete ischemia. Indian

J. Physiol. **Pharmacol.**, 39, 37, 1995.

CLM What is claimed is:

. . . of cells in the central nervous system comprising the steps of: (a) supplying at least one bioflavonoid in a suitable **pharmacological** composition; and (b) administering a therapeutically effective dose of the bioflavonoid to achieve protection of neurons from deterioration and cell. . . .

2. The method of claim 1, further comprising the steps of: (a) supplying

PD098059 in a **pharmacologically** acceptable carrier; and (b) administering the PD098059 to obtain a blood plasma concentration of between about 30 .mu.M to about. . . .

3. The method of claim 1, further comprising the steps of: (a) supplying

apigenin in a **pharmacologically** acceptable carrier; and (b) administering the apigenin to obtain a blood plasma concentrat

L12 ANSWER 1 OF 2 USPATFULL

ACCESSION NUMBER: 2002:133249 USPATFULL
TITLE: Method for combating summer eczema and malanders
INVENTOR(S): Koniger, Helmut, Munchen, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002068099	A1	20020606
APPLICATION INFO.:	US 2001-961553	A1	20010920 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-374754, filed on 13 Aug 1999, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1998-19855717	19980813
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BAKER & DANIELS, 205 W. JEFFERSON BOULEVARD, SUITE 250, SOUTH BEND, IN, 46601	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
LINE COUNT:	286	

L12 ANSWER 2 OF 2 USPATFULL

ACCESSION NUMBER: 2002:112284 USPATFULL
TITLE: Purified cochineal and method for its production
INVENTOR(S): Ichi, Takahito, Osaka, JAPAN
Koda, Takatoshi, Osaka, JAPAN
Yukawa, Chiyoki, Osaka, JAPAN
Sakata, Makoto, Osaka, JAPAN
Sato, Hiroyuki, Osaka, JAPAN
PATENT ASSIGNEE(S): SAN-EI GEN F.F.I., INC., Toyonaka-shi, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002058016	A1	20020516
APPLICATION INFO.:	US 2001-953826	A1	20010919 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2001-JP2310, filed on 23 Mar 2001, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2000-274596	20000911
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ARMSTRONG, WESTERMAN & HATTORI, LLP, 1725 K STREET, NW., SUITE 1000, WASHINGTON, DC, 20006	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	684	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 31 OF 32 USPATFULL

ACCESSION NUMBER: 86:57928 USPATFULL

TITLE: Flavonoid phosphate salts of aminoglycoside antibiotics

INVENTOR(S): Wahlig, Helmut, Darmstadt, Germany, Federal Republic of

Dingeldein, Elvira, Dreieich, Germany, Federal Republic of

Kirchlechner, Richard, Rott a. Inn, Germany, Federal Republic of

Orth, Dieter, Darmstadt, Germany, Federal Republic of Rogalski, Werner, Alsbach, Germany, Federal Republic

of

PATENT ASSIGNEE(S): Merck Patent Gesellschaft mit beschraenkter Haftung, Darmstadt, Germany, Federal Republic of (non-U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 4617293	19861014
---------------------	------------	----------

APPLICATION INFO.:	US 1984-613131	19840523 (6)
--------------------	----------------	--------------

RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1982-377779, filed on 13 May 1982, now abandoned	
-----------------------	--	--

NUMBER	DATE
--------	------

PRIORITY INFORMATION:	DE 1981-3118856	19810513
-----------------------	-----------------	----------

	DE 1982-3206725	19820225
--	-----------------	----------

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Brown, Johnnie R.

ASSISTANT EXAMINER: Peselev, Elli

LEGAL REPRESENTATIVE: Millen & White

NUMBER OF CLAIMS: 12

EXEMPLARY CLAIM: 1,11

LINE COUNT: 528

L18 ANSWER 30 OF 32 USPATFULL

ACCESSION NUMBER: 88:62483 USPATFULL

TITLE: Modification of plant extracts from zygophyllaceae and
pharmaceutical use therefor

INVENTOR(S): Jordan, Russell T., Fort Collins, CO, United States

PATENT ASSIGNEE(S): Chemex Pharmaceuticals, Inc., Denver, CO, United
States

(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4774229		19880927
APPLICATION INFO.:	US 1986-860654		19860507 (6)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1982-365784, filed on 5 Apr 1982, now abandoned which is a continuation-in-part of Ser. No. US 1979-49886, filed on 19 Jun 1979, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rollins, John		
LEGAL REPRESENTATIVE:	Kenyon & Kenyon		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
LINE COUNT:	835		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A mixture of an extract from a plant belonging to the Zygophyllaceae family containing phenolic compositions and a nonalkali metal salt is useful as a **pharmaceutical** agent, for example, in the treatment of cancer, nonmalignant tumors, osteomyelitis, psoriasis and warts.

L18 ANSWER 28 OF 32 USPATFULL

ACCESSION NUMBER: 1998:57962 USPATFULL

TITLE: Flavonoid and biflavonoid derivatives, their
pharmaceutical compositions, their anxiolytic
activity

INVENTOR(S): Cassels, Bruce Kennedy, Casilla, Chile
Dajas, Federico Jose, Montevideo, Uruguay
Medina, Jorge Horacio, Buenos Aires, Argentina
Paladini, Alejandro Constantino, Buenos Aires,
Argentina

PATENT ASSIGNEE(S): Silveira, Rodolfo Horacio, Montevideo, Uruguay
University of Strathclyde, United Kingdom (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5756538		19980526
	WO 9505169		19950223
APPLICATION INFO.:	US 1996-586796		19960531 (8)
	WO 1994-GB1803		19940817
			19960531 PCT 371 date
			19960531 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1993-17071	19930817
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Richter, Johann	
ASSISTANT EXAMINER:	Stockton, Laura L.	
LEGAL REPRESENTATIVE:	Bell Seltzer Intellectual Property Law Group of Alston & Bird LLP	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Figure(s); 19 Drawing Page(s)	

L18 ANSWER 27 OF 32 USPATFULL

ACCESSION NUMBER: 1999:110380 USPATFULL

TITLE: Use of flavones and flavonoids against the UV-induced decomposition of dibenzoylmethane and its derivatives

INVENTOR(S): Gers-Barlag, Heinrich, Kummerfeld, Germany, Federal Republic of
Scheel, Oliver, Dusseldorf, Germany, Federal Republic of

PATENT ASSIGNEE(S): Beiersdorf AG, Hamburg, Germany, Federal Republic of
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5952391		19990914
APPLICATION INFO.:	US 1998-205435		19981204 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1997-19755504	19971213
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	MacMillan, Keith D.	
ASSISTANT EXAMINER:	Kim, Vizkie	
LEGAL REPRESENTATIVE:	Sprung Kramer Schaefer & Briscoe	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	572	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Use of flavone derivatives and flavanone derivatives, in particular flavonoids for stabilizing **cosmetic** or dermatologically acceptable substances, the chemical formula of which includes the structural moiety of dibenzoylmethane, against the decomposition caused by UV radiation.

L18 ANSWER 25 OF 32 USPATFULL

ACCESSION NUMBER: 1999:167038 USPATFULL

TITLE: Flavonoid and biflavonoid derivatives, their
pharmaceutical compositions, their anxiolytic
activity

INVENTOR(S): Cassels, Bruce Kennedy, Casilla, Chile
Dajas, Federico Jose, Montevideo, Uruguay
Medina, Jorge Horacio, Buenos Aires, Argentina
Paladini, Alejandro Constantino, Buenos Aires,
Argentina

PATENT ASSIGNEE(S): Silveira, Rodolfo Horacio, Montevideo, Uruguay
University of Strathclyde, United Kingdom (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6004998		19991221
APPLICATION INFO.:	US 1997-939975		19970929 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 586796		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1993-17071	19930817
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Stockton, Laura L.	
LEGAL REPRESENTATIVE:	Alston & Bird LLP	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Figure(s); 19 Drawing Page(s)	
LINE COUNT:	637	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Certain flavonoids, notably derivatives of flavone, chrysin and apigenin, together with dimers thereof such as amentoflavone, have been found to possess anxiolytic properties (i.e., anxiety reducing properties) without exhibiting a sedative effect. Novel compounds and **pharmaceutical** formulations are also described.

L18 ANSWER 26 OF 32 USPATFULL

ACCESSION NUMBER: 1999:150659 USPATFULL

TITLE: Compositions of matter useful in the treatment of
viral

INVENTOR(S): infections derived from plant extracts
Tsai, Hsiu-Hsien, Chang-Huah, Taiwan, Province of
China

PATENT ASSIGNEE(S): Hwang, Shie-Ming, Columbus, OH, United States
Sage R&D, Columbus, OH, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5989556		19991123
APPLICATION INFO.:	US 1997-890065		19970709 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-16100P	19960710 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	

PRIMARY EXAMINER: Naff, David M.
ASSISTANT EXAMINER: Kerr, Janet M.
LEGAL REPRESENTATIVE: Nickey, Donald O. Standley & Gilcrest, LLP
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 3305

AB Compositions derived from Chinese herbal medicines, medicinal plants
and

extracts thereof, are provided for the treatment of animals infected
with viruses, especially with hepatitis B virus (HBV), hepatitis C
virus

(HCV), and human immunodeficiency virus (HIV). More specifically, the
compositions of the present invention are derived from various Chinese
herbal medicines or medicinal plants which have a long history of human
consumption. The compositions of the invention are obtained through
specific techniques and have demonstrated outstanding efficacy for
treating human HBV carriers and hepatitis C patients. Compositions
according to the invention have also exhibited in vitro antiviral
activities against murine leukemia virus (MuLV) and HIV. HIV is the
virus known to cause acquired immunodeficiency syndrome (AIDS) in

humans
and AIDS presents special problems to the medical community which the
present invention addresses. Preferred compositions contain the herbal
ingredients AEGINETIAE HERBA, BLECHNI RHIZOMA, LESPEDEZAE HERBA,
POLYGONI CUSPIDATI RHIZOMA, FORSYTHIAE FRUCTUS, and LIGUSTRI FRUCTUS,

or
contain the herbal ingredients AEGINETIAE HERBA, LONICERAE FLOS,
PRUNELLAE SPICA, and LESPEDEZAE HERBA.